Case Report

Severe Hypoglycemia Due To the Administration of Bromocriptine in a Non-Diabetic Patient: A Case Study

Abstract

The patient was a 24-year-old man with persistent vegetative state following severe traumatic brain injury due to a car accident, who was referred to the emergency department with a generalized tonic-clonic seizure due to severe hypoglycemia. The patient was treated with phenytoin, levetiracetam, bromocriptine and enoxaparine. The patient was transferred to the Intensive Care Unit (ICU) for accurate monitoring. The patient in the ICU was treated with 100 cc/h of Dextrose 10% plus Intravenous antibiotic to treat urinary tract infection induced sepsis. The previous prescribed medications were also prescribed. Despite proper feeding through PEG tube and receiving 100 cc/h of Dextrose 10%, the patient’s blood glucose was dropped frequently below 50 mg/dl and hypertonic glucose infusion was several times required for treatment of hypoglycemia. Administration of bromocriptine as antidiabetic agent was eliminated after consultation with a neurologist surgeon. After bromocriptine discontinuation, hypoglycemia was resolved. In this non-diabetic patient, severe hypoglycemia occurred after administration of bromocriptine, which was an unusual complication in the non-diabetic patient treated with bromocriptine.

[1] Celik JB, Duman A, Arun O, Onal IO, Ilban O, Sonmez AE. Dopaminergic challenge with bromocriptine in patients with severe brain injury. Intensive Care Medicine Experimental. 2015; 3(1):1-2. [DOI:10.1186/2197-425X-3-S1-A485] [PMCID]
[2] Munakomi S, Bhattarai B, Kumar BM. Role of bromocriptine in multi-spectral manifestations of traumatic brain injury. Chinese Journal of Traumatology. 2017; 20(2):84-6. [DOI:10.1016/j. cjtee.2016.04.009] [PMID] [PMCID]
[3] Passler MA, Riggs RV. Positive outcomes in traumatic brain injury– vegetative state: Patients treated with bromocriptine. Archives of Physical Medicine and Rehabilitation. 2001; 82(3):311-5. [DOI:10.1053/apmr.2001.20831] [PMID]
[4] Shivaprasad C, Kalra S. Bromocriptine in type 2 diabetes mellitus. Indian Journal of Endocrinology and Metabolism. 2011; 15(Suppl1):S17. [DOI:10.4103/2230-8210.83058] [PMID] [PMCID]
[5] DeFronzo RA. Bromocriptine: A sympatholytic, D2-dopamine agonist for the treatment of type 2 diabetes. Diabetes Care. 2011; 34(4):789-94. [DOI:10.2337/dc11-0064] [PMID] [PMCID]
[6] Pijl H, Ohashi S, Matsuda M, Miyazaki Y, Mahankali A, Kumar V, et al. Bromocriptine: A novel approach to the treatment of type 2 diabetes. Diabetes Care. 2000; 23(8):1154-61. [DOI:10.2337/diace- are.23.8.1154] [PMID]
[7] Garg KK, Chugh SN. Bromocriptine mesylate in type 2 diabetes mellitus: A novel approach. International Journal of Medical Science and Public Health. 2017; 6(6):987-92.[DOI:10.5455/ijmm- sph.2017.0308007042017]
[8] Bahler L, Verberne HJ, Brakema E, Tepaske R, Booij J, Hoekstra JB, et al. Bromocriptine and insulin sensitivity in lean and obese subjects. Endocrine Connections. 2016; 5(6):44-52. [DOI:10.1530/EC- 16-0051] [PMID] [PMCID]
[9] Cincotta AH, Meier AH, Cincotta Jr M. Bromocriptine improves glycaemic control and serum lipid profile in obese Type 2 diabetic subjects: A new approach in the treatment of diabetes. Expert Opinion on Investigational Drugs. 1999; 8(10):1683-707. [DOI:10.1517/135 43784.8.10.1683] [PMID]
[10] Sando KR, Taylor J. Bromocriptine: Its place in type 2 diabetes Tx. Priority Updates to Research Literature (PURLs). 2011; 60 (11):E1-5. [PMID] [DOI:10.2337/diacare.23.8.1154]
[11] Florez H, Scranton R, Farwell WR, DeFronzo RA, Ezrokhi M, Gaziano JM, et al. Randomized clinical trial assessing the efficacy and safety of bromocriptine-QR when added to ongoing thiazolidinedione therapy in patients with type 2 diabetes mellitus. Journal of Diabetes & Metabolism. 2011; 2(7):142. [DOI:10.4172/2155- 6156.1000142]
[12] Bernard N, Jantzem H, Becker M, Pecriaux C, Bénard-Laribière A, Montastruc JL, et al., the French Network of Regional Pharmacovigilance Centres. Severe adverse effects of bromocriptine in lactation inhibition: A pharmacovigilance survey. International Journal of Obstetrics & Gynaecology. 2015; 122(9):1244-51. [DOI:10.1111/1471- 0528.13352] [PMID]
[13] Melmed S. Williams textbook of endocrinology. Amsterdam: Elsevier Health Sciences; 2016. https://books.google.com/books?id
[14] Ramaker CC, Stowe R, Ives N. Bromocriptine versus levodopa in early Parkinson's disease. Cochrane Database of Systematic Reviews. 2007(4). [DOI:10.1002/14651858.CD002258]
[15] Parkes JD, Debono AG, Marsden CD. Bromocriptine in Parkinsonism: Long-term treatment, dose response, and comparison with levodopa. Journal of Neurology, Neurosurgery & Psychiatry. 1976; 39(11):1101-8.[DOI:10.1136/jnnp.39.11.1101] [PMID] [PMCID]
Files
IssueVol 5 No 3 (2020): Summer QRcode
SectionCase Report(s)
Published2020-11-24
DOI https://doi.org/10.18502/crcp.v5i3.4361
Keywords
Bromocriptine Hypoglycemia Diabetes mellitus Brain injuries

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
1.
Choobkar S, Nazarpoor S, kaviani M. Severe Hypoglycemia Due To the Administration of Bromocriptine in a Non-Diabetic Patient: A Case Study. CRCP. 2020;5(3):77-80.